Ya-Xin Lou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ya-Xin Lou has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Baoxue Yang
Department of Pharmacology, School of Basic Medical Sciences Peking University Beijing China
1 shared publication - Chuang Lu
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
1 shared publication - Dan Liu
Proteomics Laboratory, Medical and Healthy Analytical Center, Peking University Health Science Center, Beijing, 100191, People's Republic of China
1 shared publication - Guangmin Zuo
Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China
1 shared publication - Guo-Liang Zhang
Department of Pharmacology, School of Basic Medical Sciences Peking University Beijing China
1 shared publication - Hua Zhang
Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
1 shared publication
Latest Publications
- Open Access
Gastric Juice Metabolic Reprogramming Along Correa’s Cascade: Discovery and Validation of a Metabolite Panel for Non-Invasive Early Detection of Gastric Cancer
Detection and endoscopic removal of EGC effectively reduced GC-caused mortality, yet no effective non-invasive screening approaches have been clinically used. Gastric juice integrates tissue- and gastric-microbiome-derived metabolites, making it a promising biofluid for screening EGC. To systematically profile metabolic reprogramming in gastric juice during gastric tumorigenesis, we carried out untargeted metabolic profiling in the discovery cohort enrolling patients at different stages along Correa’s cascade. We identified similar metabolic landscapes between HGD and EGC patients, which significantly differed from those of gastritis and intestinal metaplasia stages. These altered metabolites were subjected to origin analysis, revealing an association of both tumorigenesis-induced tissue metabolic reprogramming and gastric microbiome metabolic reprogramming, as supported by catalytic enzyme changes between tumor and adjacent normal tissues, and by bacteria-derived indole metabolites that correlated with altered gastric bacteria in GC patients. Least absolute shrinkage and selection operator (LASSO) was used for biomarker screening, and the selected metabolites were transferred into MRM-based targeted metabolic detection. A 4-metabolite panel-based diagnostic model was established in the discovery cohort and evaluated in an independent validation cohort, yielding an AUC of 0.90 (90.0% sensitivity, 79.0% specificity), with all three HGD and 20 of 23 EGC cases correctly classified. With the aid of endogastric capsules for non-invasive acquisition of gastric juice, our gastric juice metabolite-based test provides proof-of-concept evidence for its clinical utility in the early detection of GC and precancerous dysplasia.
Open AccessGastric Juice Metabolic Reprogramming Along Correa’s Cascade: Discovery and Validation of a Metabolite Panel for Non-Invasive Early Detection of Gastric Cancer
Detection and endoscopic removal of EGC effectively reduced GC-caused mortality, yet no effective non-invasive screening approaches have been clinically used. Gastric juice integrates tissue- and gastric-microbiome-derived metabolites, making it a promising biofluid for screening EGC. To systematically profile metabolic reprogramming in gastric juice during gastric tumorigenesis, we carried out untargeted metabolic profiling in the discovery cohort enrolling patients at different stages along Correa’s cascade. We identified similar metabolic landscapes between HGD and EGC patients, which significantly differed from those of gastritis and intestinal metaplasia stages. These altered metabolites were subjected to origin analysis, revealing an association of both tumorigenesis-induced tissue metabolic reprogramming and gastric microbiome metabolic reprogramming, as supported by catalytic enzyme changes between tumor and adjacent normal tissues, and by bacteria-derived indole metabolites that correlated with altered gastric bacteria in GC patients. Least absolute shrinkage and selection operator (LASSO) was used for biomarker screening, and the selected metabolites were transferred into MRM-based targeted metabolic detection. A 4-metabolite panel-based diagnostic model was established in the discovery cohort and evaluated in an independent validation cohort, yielding an AUC of 0.90 (90.0% sensitivity, 79.0% specificity), with all three HGD and 20 of 23 EGC cases correctly classified. With the aid of endogastric capsules for non-invasive acquisition of gastric juice, our gastric juice metabolite-based test provides proof-of-concept evidence for its clinical utility in the early detection of GC and precancerous dysplasia.
- Open Access
- 8 August 2018
- Published by MDPI AG in Pharmaceutics
- Vol. 10 (3) , 124
Pharmacokinetics, Tissue Distribution and Excretion of a Novel Diuretic (PU-48) in Rats
Methyl 3-amino-6-methoxythieno [2,3-b] quinoline-2-carboxylate (PU-48) is a novel diuretic urea transporter inhibitor. The aim of this study is to investigate the profile of plasma pharmacokinetics, tissue distribution, and excretion by oral dosing of PU-48 in rats. Concentrations of PU-48 within biological samples are determined using a validated high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. After oral administration of PU-48 (3, 6, and 12 mg/kg, respectively) in self-nanomicroemulsifying drug delivery system (SNEDDS) formulation, the peak plasma concentrations (Cmax), and the area under the curve (AUC0–∞) were increased by the dose-dependent and linear manner, but the marked different of plasma half-life (t1/2) were not observed. This suggests that the pharmacokinetic profile of PU-48 prototype was first-order elimination kinetic characteristics within the oral three doses range in rat plasma. Moreover, the prototype of PU-48 was rapidly and extensively distributed into thirteen tissues, especially higher concentrations were detected in stomach, intestine, liver, kidney, and bladder. The total accumulative excretion of PU-48 in the urine, feces, and bile was less than 2%. This research is the first report on disposition via oral administration of PU-48 in rats, and it provides important information for further development of PU-48 as a diuretic drug candidate.
- 8 August 2018
- Published by MDPI AG in Pharmaceutics
- Vol. 10 (3) , 124
Open AccessPharmacokinetics, Tissue Distribution and Excretion of a Novel Diuretic (PU-48) in Rats
Methyl 3-amino-6-methoxythieno [2,3-b] quinoline-2-carboxylate (PU-48) is a novel diuretic urea transporter inhibitor. The aim of this study is to investigate the profile of plasma pharmacokinetics, tissue distribution, and excretion by oral dosing of PU-48 in rats. Concentrations of PU-48 within biological samples are determined using a validated high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. After oral administration of PU-48 (3, 6, and 12 mg/kg, respectively) in self-nanomicroemulsifying drug delivery system (SNEDDS) formulation, the peak plasma concentrations (Cmax), and the area under the curve (AUC0–∞) were increased by the dose-dependent and linear manner, but the marked different of plasma half-life (t1/2) were not observed. This suggests that the pharmacokinetic profile of PU-48 prototype was first-order elimination kinetic characteristics within the oral three doses range in rat plasma. Moreover, the prototype of PU-48 was rapidly and extensively distributed into thirteen tissues, especially higher concentrations were detected in stomach, intestine, liver, kidney, and bladder. The total accumulative excretion of PU-48 in the urine, feces, and bile was less than 2%. This research is the first report on disposition via oral administration of PU-48 in rats, and it provides important information for further development of PU-48 as a diuretic drug candidate.